Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
FDA approval of AMDS is a major near-term catalyst, with added portfolio upside from the Endospan acquisition. Q1 2026 revenue rose 18% YoY and adjusted EBITDA rose 26%, while the stock gained about 21% over 21 trading days and closed at a fresh short-term high on 2026-07-28.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity Position ⢠Rising Debt Burden ⢠Weakening Profitability Trend AORT's strong margins and liquidity are outweighed by deteriorating quarterly losses, rising acquisition-funded leverage, negative free cash flow, and an expensive valuation, warranting caution.
Price Behavior
Key Price Behavior Insights: ⢠Last-month decline ⢠Oversold rebound ⢠Key support Support Level: $24.65â$25.00 Resistance Level: $25.60â$26.00 AORT remains in a last-month downtrend, but oversold RSI supports rebound potential above $25.60â$26.00 while a break below $24.65 would signal renewed weakness.
AI Summary
AORT is now a higher-upside aortic-platform bet driven by AMDS and Endospan, but its investment case hinges on proving these launches convert growth into GAAP profits, positive free cash flow, and debt reduction; investors should wait for adoption and cash-conversion evidence before underwriting the premium valuation.
Description
Artivion Inc. develops, manufactures and distributes medical devices and implantable human tissues for cardiac, vascular, thoracic and general surgical procedures worldwide. Its portfolio combines biologic materials, synthetic vascular grafts, surgical sealants, hemostatic agents, prosthetic heart valves and a range of endovascular stent graft systems and preservation and coating services for device makers. The company serves hospitals and surgeons, was founded in 1984, and changed its name from CryoLife, Inc. to Artivion Inc. in January 2022, with headquarters in Kennesaw, Georgia.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 28 | Aug 4 | AORT | Artivion, Inc. | FDA approval of AMDS is a major near-term catalyst, with added portfolio upside from the Endospan acquisition. Q1 2026 revenue rose 18% YoY and adjusted EBITDA rose 26%, while the stock gained about 21% over 21 trading days and closed at a fresh short-term high on 2026-07-28. | Closed | -0.4% |
| Jul 21 | Jul 28 | AORT | Artivion, Inc. | Catalyst-rich medtech setup with Q1 2026 revenue up 18% YoY, adjusted EBITDA up 26%, FDA PMA approval for NEXUS, acquisition of Endospan, and FDA PMA approval for AMDS Hybrid Prosthesis on 2026-06-29 opening an estimated $150M U.S. market. | Closed | +8.3% |
| Jul 14 | Jul 21 | AORT | Artivion, Inc. | Recent medical-device catalyst: FDA approved AMDS Hybrid Prosthesis on 2026-06-29, expanding the U.S. commercial path, and the Endospan acquisition closed on 2026-05-18. Q1 2026 revenue rose 18% YoY and the stock is up about 14.8% over 21 trading days. | Closed | +7.8% |
| Jul 6 | Jul 13 | AORT | Artivion, Inc. | Recent regulatory catalysts are substantial: FDA PMA approval for NEXUS on 2026-04-07, Endospan acquisition completion on 2026-05-18, and FDA approval of AMDS on 2026-06-29. AMDS opens an estimated $150M annual U.S. market, and the stock is up about 18% over 21 trading days. | Closed | -2.5% |
| Jun 29 | Jul 6 | AORT | Artivion, Inc. | Fresh medical-device catalyst with improving operations: AORT received FDA PMA approval for AMDS Hybrid Prosthesis on 2026-06-29 after prior NEXUS Aortic Arch approval on 2026-04-07 and Endospan acquisition completion on 2026-05-18; Q1 2026 revenue rose 18% YoY to $116.3M and adjusted EBITDA rose 26% to $22.1M. | Closed | +10.1% |